About Slate Medicines
Slate Medicines is a clinical-stage biotech company developing next-generation therapeutics for migraine and other headache disorders. Its lead program, SLTE-1009, is a subcutaneous monoclonal antibody targeting both PACAP and VIP, with the potential to be a best-in-class option for migraine prevention; the program entered Phase 1 in 2026, with topline data expected in mid-2027 and a Phase 2 start planned for 2027.
Description
About Slate Medicines
Slate Medicines is a clinical-stage biotech company developing next-generation therapeutics for migraine and other headache disorders. Its lead program, SLTE-1009, is a subcutaneous monoclonal antibody targeting both PACAP and VIP, with the potential to be a best-in-class option for migraine prevention; the program entered Phase 1 in 2026, with topline data expected in mid-2027 and a Phase 2 start planned for 2027.
Slate is backed by leading healthcare investors including RA Capital Management, Forbion, Foresite Capital, and Frazier Life Sciences, and is on track to become a publicly traded company (Nasdaq: SLTE) through a planned merger with Fulcrum Therapeutics.
- Own in vitro and in vivo target validation strategy from early target hypothesis through development candidate (DC) nomination, including cell-based and animal models that establish target engagement, mechanism of action, and translatability to the clinic
- Lead GPCR and ion channel pharmacology, including PACAP/VIP receptor biology (PAC1, VPAC1, VPAC2), and apply that expertise to new targets as the pipeline grows
- Build and validate disease-relevant in vivo models, such as migraine pharmacology models, that produce decision-grade efficacy and mechanism data for go/no-go calls
- Build a discovery function that isn’t tied to one modality: support biologics today and small molecules, peptides or other modalities as the pipeline expands, and partner with the CSO on choosing the right modality for each new target
- Define discovery-to-development handoff criteria so programs enter nonclinical development with validated targets, characterized mechanism and de-risked biology
- Lead programs from target validation through DC nomination and handoff to nonclinical toxicology, with personal accountability for scientific rigor and timelines
- Select and manage the external CRO network, including overseas partners, for in vitro pharmacology, in vivo models, antibody/protein generation and cell line development, and hold them to Slate’s scientific standards and timelines
- Lead discovery-stage scientific due diligence for in-licensing, collaboration and acquisition opportunities
- Build and lead a discovery team known for scientific rigor and execution
Requirements
- PhD in pharmacology, cell/molecular biology, biochemistry, or a related discipline
- 12–15+ years of discovery research leadership in biotech or pharma, with the Executive Director level reserved for candidates with a broader and longer track record
- Deep, hands-on GPCR and ion channel pharmacology experience, including receptor/channel subtype characterization and functional assays
- Demonstrated, evidenced track record of personally moving at least one program from target validation through nonclinical toxicology into clinical development — named programs and outcomes, not oversight alone
- Direct experience managing external CROs for in vitro and in vivo pharmacology, with accountability for data quality and timelines
- Experience working across more than one therapeutic modality, or clear evidence of operating modality agnostically rather than being wedded to one
- Demonstrated ability to build and lead a high-performing discovery organization with a reputation beyond the company itself
Preferred Qualifications
- Neurology, migraine, or headache disorder discovery experience
- Direct antibody discovery/engineering experience (e.g., phage display, hybridoma, humanization) in addition to small-molecule or peptide discovery
- Experience building a discovery function from an early- or growth-stage biotech, including standing up processes and vendor networks from a lean starting point
- Experience designing cross-functional discovery-to-nonclinical-to-clinical handoff processes
- Experience with both CNS-penetrant and peripherally restricted therapeutic strategies
Benefits
- Health Care Plan (Medical, Dental & Vision)
- Retirement Plan (401k, IRA)
- Life Insurance (Basic, Voluntary & AD&D)
- Paid Time Off (Vacation, Sick & Public Holidays)
- Short Term & Long Term Disability
- Stock Option Plan